Amylyx Pharmaceuticals, INC Schedule 13G passive stakes

Perceptive Advisors LLC and Joseph Edelman have reported a 7.5% beneficial ownership stake in Amylyx Pharmaceuticals, Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Amylyx Pharmaceuticals Inc. following an internal realignment.

Adage Capital Management and its principals have reduced their beneficial ownership in Amylyx Pharmaceuticals, Inc. to 2.53%.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 15.0% beneficial ownership stake in Amylyx Pharmaceuticals Inc. common stock as of December 31, 2025.

The Vanguard Group has reported a 5.28% beneficial ownership stake in Amylyx Pharmaceuticals Inc., holding 5,804,912 shares of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.1% beneficial ownership stake in Amylyx Pharmaceuticals, Inc. as of December 31, 2025.

Commodore Capital LP and its affiliates have reported a 5.1% beneficial ownership stake in Amylyx Pharmaceuticals, Inc., holding 5,650,000 shares of common stock.

Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly reported a 2.6% beneficial ownership stake in Amylyx Pharmaceuticals, Inc.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., reported a passive beneficial ownership of 8.2% in Amylyx Pharmaceuticals, Inc.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 6.39% beneficial ownership stake in Amylyx Pharmaceuticals, Inc. as of September 30, 2025.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.94% beneficial ownership in Amylyx Pharmaceuticals Inc.

FMR LLC and Abigail P. Johnson have reported a 10.7% beneficial ownership stake in Amylyx Pharmaceuticals Inc., totaling 11,379,207 common shares.

Adage Capital Management and its principals have reported a 9.87% beneficial ownership stake in Amylyx Pharmaceuticals, holding 8.8 million shares.

The Vanguard Group has reported a 5.04% passive beneficial ownership stake in Amylyx Pharmaceuticals Inc., holding 4,498,028 shares of common stock.

BlackRock, Inc. has disclosed a beneficial ownership of 5.5% of Amylyx Pharmaceuticals, Inc.'s common stock, totaling 4,917,501 shares, as of June 30, 2025.

Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen have jointly disclosed a passive beneficial ownership of 5.3% in Amylyx Pharmaceuticals, Inc., totaling 4,717,709 shares of common stock.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a collective beneficial ownership of 8.8% in Amylyx Pharmaceuticals, Inc.

Point72 Asset Management, along with its affiliates and Steven A. Cohen, has disclosed a 1.2% beneficial ownership stake in Amylyx Pharmaceuticals, Inc., totaling 1,048,343 shares as of March 31, 2025.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a 6.43% beneficial ownership stake in Amylyx Pharmaceuticals, Inc., totaling 5,697,605 shares of common stock.

Panacea Venture Healthcare Fund II, L.P. and its affiliated entities, including James Huang, have reported a 2.6% passive beneficial ownership stake in Amylyx Pharmaceuticals, Inc. as of December 31, 2024.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have jointly reported a 7.9% beneficial ownership stake in Amylyx Pharmaceuticals, Inc., totaling 6,774,348 shares.

Point72 Asset Management, along with its affiliates and founder Steven A. Cohen, has disclosed a beneficial ownership of 5.6% in Amylyx Pharmaceuticals, Inc., totaling 4,820,333 shares.